Notice2026-09715
Glycine From India: Preliminary Results and Rescission, in Part, of Antidumping Duty Administrative Review; 2024-2025
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 14, 2026
Issuing agencies
Commerce DepartmentInternational Trade Administration
Abstract
The U.S. Department of Commerce (Commerce) preliminarily determines that producers and/or exporters subject to this administrative review made sales of subject merchandise at less than normal value (NV) during the period of review (POR), June 1, 2024, through May 31, 2025. In addition, we are rescinding the review with respect to 27 companies. Interested parties are invited to comment on these preliminary results.
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 93 (Thursday, May 14, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 93 (Thursday, May 14, 2026)]
[Notices]
[Pages 27262-27264]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-09715]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
International Trade Administration
[A-533-883]
Glycine From India: Preliminary Results and Rescission, in Part,
of Antidumping Duty Administrative Review; 2024-2025
AGENCY: Enforcement and Compliance, International Trade Administration,
Department of Commerce.
SUMMARY: The U.S. Department of Commerce (Commerce) preliminarily
determines that producers and/or exporters subject to this
administrative review made sales of subject merchandise at less than
normal value (NV) during the period of review (POR), June 1, 2024,
through May 31, 2025. In addition, we are rescinding the review with
respect to 27 companies. Interested parties are invited to comment on
these preliminary results.
DATES: Applicable May 14, 2026.
FOR FURTHER INFORMATION CONTACT: Tyler Weinhold, AD/CVD Operations,
Office VI, Enforcement and Compliance, International Trade
Administration, U.S. Department of Commerce, 1401 Constitution Avenue
NW, Washington, DC 20230; telephone: (202) 482-1121.
SUPPLEMENTARY INFORMATION:
Background
On July 25, 2025, based on timely requests for review, in
accordance with 19 CFR 351.221(c)(1)(i), we initiated an administrative
review the antidumping duty order on glycine from India.\1\ On
September 10, 2026, Commerce selected Avid Organics Private Limited
(Avid) and Mulji Mehta Enterprises (Mulji Mehta) as the mandatory
respondents in this review.\2\ On October 23, 2025, Avid timely
withdrew its request for review of itself; \3\ and DPG timely withdrew
its administrative review requests for certain companies identified in
the Initiation Notice, including Avid.\4\ Further, on December 5, 2025,
Paras Intermediates Private Limited timely withdrew its review request
for itself.\5\ On December 9, 2025, Commerce selected Medilane
Healthcare Private Limited (Medilane), the only other company subject
to this review in addition to Mulji Mehta, as an additional mandatory
respondent.\6\
---------------------------------------------------------------------------
\1\ See Initiation of Antidumping and Countervailing Duty
Administrative Reviews, 90 FR 35268 (July 25, 2025) (Initiation
Notice); see also Glycine from India and Japan: Amended Final
Affirmative Antidumping Duty Determination and Antidumping duty
Orders, 84 FR 29170 (June 21, 2019) (Order).
\2\ See Memorandum, ``Respondent Selection,'' dated September
10, 2025.
\3\ See Avid's Letter, ``Withdrawal of Review Request of Anti-
Dumping Duty Administrative Review for review period 2024-2025,''
dated October 23, 2025.
\4\ See DPG's Letter, ``Partial Withdrawal of Request for
Administrative Review,'' dated October 23, 2025; see also DPG's
Letter, ``Corrected Partial Withdrawal of Request for Administrative
Review,'' dated December 8, 2025.
\5\ See Paras' Letter, ``Withdrawal of Review Request for Anti-
Dumping Duty Administrative Review,'' dated December 5, 2025.
\6\ See Memorandum, ``Selection of Medilane Healthcare Private
Limited as a Mandatory Respondent,'' dated December 9, 2025.
---------------------------------------------------------------------------
Due to the lapse in appropriations and Federal Government shutdown,
on November 14, 2025, Commerce tolled all deadlines in administrative
proceedings by 47 days.\7\ Additionally, due to a backlog of documents
that were electronically filed via Enforcement and Compliance's
Antidumping and Countervailing Duty Centralized Electronic Service
System (ACCESS) during the Federal Government shutdown, on November 24,
2025, Commerce tolled all deadlines in administrative proceedings by an
additional 21 days.\8\ On December 22, 2025, Commerce extended the time
limit for these preliminary results in accordance with section
751(a)(3)(A).\9\ Accordingly, the deadline for these preliminary
results is now May 11, 2026.
---------------------------------------------------------------------------
\7\ See Memorandum, ``Deadlines Affected by the Shutdown of the
Federal Government,'' dated November 14, 2025.
\8\ See Memorandum, ``Tolling of all Case Deadlines,'' dated
November 24, 2025.
\9\ See Memorandum, ``Extension of Deadline for Preliminary
Results of Antidumping Duty Administrative Review,'' dated December
22, 2025.
---------------------------------------------------------------------------
For a complete description of the events that followed the
initiation of this review, see the Preliminary Decision Memorandum.\10\
A list of the topics discussed in the Preliminary Decision Memorandum
is attached as Appendix I to this notice. The Preliminary Decision
Memorandum is a public document and is on file electronically via
Enforcement and Compliance's Antidumping and Countervailing Duty
Centralized Electronic Service System (ACCESS). ACCESS is available to
registered users at <a href="https://access.trade.gov">https://access.trade.gov</a>. In addition, a complete
version of the Preliminary Decision Memorandum can be accessed directly
at <a href="https://access.trade.gov/frnotices">https://access.trade.gov/frnotices</a>.
---------------------------------------------------------------------------
\10\ See Memorandum, ``Decision Memorandum for the Preliminary
Results of the Administrative Review of the Antidumping Duty Order
on Glycine from India; 2024-2025,'' dated concurrently with, and
hereby adopted by, this notice (Preliminary Decision Memorandum).
---------------------------------------------------------------------------
Scope of the Order
The merchandise subject to the Order is glycine from India. For a
complete description of the scope of the Order, see the Preliminary
Decision Memorandum.
Rescission of Administrative Review, in Part
Pursuant to 19 CFR 351.213(d)(1), Commerce will rescind an
administrative review, in whole or in part, if a party who requested a
review withdraws its request within 90 days of the date of publication
of notice of initiation. As noted above, Commerce received timely-filed
withdrawal requests with respect to the companies listed in Appendix
II, and no other parties requested an administrative review of these
companies. Therefore, we are rescinding this administrative review with
respect to these companies, pursuant to 19 CFR 351.213(d)(1).
[[Page 27263]]
Methodology
Commerce is conducting this review in accordance with section
751(a) of the Tariff Act of 1930, as amended (the Act). In addition,
Commerce has relied entirely on facts available with adverse inferences
under sections 776(a) and (b) of the Act for Medilane Healthcare
Private Limited and Mulji Mehta. For a full description of the
methodology underlying our conclusions, see the Preliminary Decision
Memorandum.
Preliminary Results of Review
As a result of this review, we preliminarily determine the
following estimated weighted-average dumping margins exist for the
period June 1, 2024, through May 31, 2025:
------------------------------------------------------------------------
Weighted- average
Producer/exporter dumping margin
(percent)
------------------------------------------------------------------------
Medilane Healthcare Private Limited.................. 57.17
Mulji Mehta Enterprises.............................. 57.17
------------------------------------------------------------------------
Disclosure
Normally, Commerce discloses to interested parties the calculations
performed in preliminary results within five days of any public
announcement or, if there is no public announcement, within five days
of the date of publication of the notice of preliminary results in the
Federal Register, in accordance with 19 CFR 351.224(b). However,
because Commerce preliminarily applied adverse facts available with
adverse inferences to the individually examined companies, in
accordance with section 776 of the Act, there are no calculations to
disclose.
Public Comment
Case briefs or other written comments may be submitted to the
Assistant Secretary for Enforcement and Compliance. Pursuant to 19 CFR
351.309(c)(1)(ii), we have modified the deadline for interested parties
to submit case briefs to Commerce to no later than 21 days after the
date of the publication of this notice.\11\ Rebuttal briefs, limited to
issues raised in the case briefs, may be filed not later than five days
after the date for filing case briefs.\12\ Interested parties who
submit case briefs or rebuttal briefs in this proceeding must submit:
(1) a table of contents listing each issue; and (2) a table of
authorities.\13\
---------------------------------------------------------------------------
\11\ See 19 CFR 351.309.
\12\ See 19 CFR 351.309(d); see also Administrative Protective
Order, Service, and Other Procedures in Antidumping and
Countervailing Duty Proceedings, 88 FR 67069, 67077 (September 29,
2023) (APO and Service Procedures).
\13\ See 19 CFR 351.309(c)(2) and (d)(2).
---------------------------------------------------------------------------
As provided under 19 CFR 351.309(c)(2)(iii) and (d)(2)(iii), we
request that interested parties provide at the beginning of their
briefs a public executive summary for each issue raised in their
briefs.\14\ Further, we request that interested parties limit their
public executive summary of each issue to no more than 450 words, not
including citations. We intend to use the public executive summaries as
the basis of the comment summaries included in the issues and decision
memorandum that will accompany the final results in this administrative
review. We request that interested parties include footnotes for
relevant citations in the public executive summary of each issue. Note
that Commerce has amended certain of its requirements pertaining to the
service of documents in 19 CFR 351.303(f).\15\
---------------------------------------------------------------------------
\14\ We use the term ``issue'' here to describe an argument that
Commerce would normally address in a comment of the Issues and
Decision Memorandum.
\15\ See APO and Service Procedures.
---------------------------------------------------------------------------
Pursuant to 19 CFR 351.310(c), interested parties who wish to
request a hearing must submit a written request to the Assistant
Secretary for Enforcement and Compliance, filed electronically via
ACCESS by 5:00 p.m. Eastern Time within 30 days after the date of
publication of this notice. Requests should contain: (1) the party's
name, address, and telephone number; (2) the number of participants;
and (3) a list of issues to be discussed. Oral presentations at the
hearing will be limited to issues raised in the briefs. If a request
for a hearing is made, Commerce will inform parties of the scheduled
date for the hearing.\16\
---------------------------------------------------------------------------
\16\ See 19 CFR 351.310(d).
---------------------------------------------------------------------------
All submissions, including case and rebuttal briefs, as well as
hearing requests, should be filed via ACCESS.\17\ An electronically
filed document must be received successfully in its entirety by ACCESS
by 5:00 p.m. Eastern Time on the established deadline.
---------------------------------------------------------------------------
\17\ See 19 CFR 351.303.
---------------------------------------------------------------------------
Assessment Rates
Pursuant to section 751(a)(2)(A) of the Act and 19 CFR
351.212(b)(1), Commerce shall determine, and U.S. Customs and Border
Protection (CBP) shall assess, antidumping duties on all appropriate
entries of subject merchandise in accordance with the final results of
this review.
If the mandatory respondent's weighted-average dumping margin is
not zero or de minimis (i.e., less than 0.50 percent) in the final
results of this review, Commerce intends to calculate importer-specific
assessment rates on the basis of the ratio of the total amount of
dumping calculated for each importer's examined sales to the total
entered value of those sales. Where we do not have entered values for
all U.S. sales to a particular importer, we will calculate an importer-
specific, per-unit assessment rate on the basis of the ratio of the
total amount of dumping calculated for the importer's examined sales to
the total quantity of those sales.\18\ To determine whether an
importer-specific, per-unit assessment rate is de minimis, in
accordance with 19 CFR 351.106(c)(2), we also will calculate an
importer-specific ad valorem ratio based on estimated entered values.
If the mandatory respondents' weighted-average dumping margin is zero
or de minimis in the final results of review, or if an importer-
specific assessment rate is zero or de minimis, Commerce will instruct
CBP to liquidate appropriate entries without regard to antidumping
duties.\19\
---------------------------------------------------------------------------
\18\ See 19 CFR 351.212(b)(1).
\19\ Id.; see also 77 FR at 8102-03; see also 19 CFR
351.106(c)(2).
---------------------------------------------------------------------------
In accordance with Commerce's ``automatic assessment'' practice,
for entries of subject merchandise during the POR produced by the
mandatory respondents for which they did not know that the merchandise
was destined for the United States, we intend to instruct CBP to
liquidate those entries at the all-others rate calculated in the less-
than-fair-value (LTFV) investigation if there is no rate for the
intermediate companies involved in the transaction.\20\
---------------------------------------------------------------------------
\20\ For a full discussion of this practice, see Antidumping and
Countervailing Duty Proceedings: Assessment of Antidumping Duties,
68 FR 23954 (May 6, 2003).
---------------------------------------------------------------------------
For the companies listed in Appendix II for which the review is
being rescinded, Commerce will instruct CBP to assess antidumping
duties on all appropriate entries. Antidumping duties shall be assessed
at rates equal to the cash deposit rate for estimated antidumping
duties required at the time of entry, or withdrawal from warehouse, for
consumption, in accordance with 19 CFR 351.212(c)(1)(i). Commerce
intends to issue rescission instructions to CBP no earlier than 35 days
after the date of publication of this notice in the Federal Register.
Commerce intends to issue assessment instructions to CBP regarding
Medilane and Mulji Mehta no earlier than 35 days after the date of
publication of the final results of this review in the Federal
Register. If a
[[Page 27264]]
timely summons is filed at the U.S. Court of International Trade, the
assessment instructions will direct CBP not to liquidate relevant
entries until the time for parties to file a request for a statutory
injunction has expired (i.e., within 90 days of publication).
Cash Deposit Requirements
The following cash deposit requirements will be effective upon
publication in the Federal Register of the final results of this
administrative review for all shipments of the subject merchandise
entered, or withdrawn from warehouse, for consumption on or after the
date of publication, as provided by section 751(a)(2)(C) of the Act:
(1) the cash deposit rate for companies listed above will be that
established in the final results of this review, except if the rate is
less than 0.50 percent and, therefore, de minimis within the meaning of
19 CFR 351.106(c)(1), in which case the cash deposit rate will be zero;
(2) for previously investigated or reviewed companies not covered by
this review, the cash deposit rate will continue to be the company-
specific cash deposit rate published for the most recently completed
segment of this proceeding in which the company participated; (3) if
the exporter is not a firm covered in this review, a prior review, or
the LTFV investigation but the manufacturer is, then the cash deposit
rate will be the rate established in the most recently completed
segment of the proceeding for the producer of the merchandise; and (4)
the cash deposit rate for all other manufacturers or exporters will
continue to be 7.23 percent, the all-others rate established in the
LTFV investigation.\21\ These cash deposit requirements, when imposed,
shall remain in effect until further notice.
---------------------------------------------------------------------------
\21\ See Order.
---------------------------------------------------------------------------
Notification to Importers
This notice also serves as a preliminary reminder to importers of
their responsibility under 19 CFR 351.402(f)(2) to file a certificate
regarding the reimbursement of antidumping and/or countervailing duties
prior to liquidation of the relevant entries during this review period.
Failure to comply with this requirement could result in Commerce's
presumption that reimbursement of antidumping and/or countervailing
duties occurred and the subsequent assessment of double antidumping
duties, and/or an increase in the amount of antidumping duties by the
amount of the countervailing duties.
Notification to Interested Parties
We are issuing and publishing these preliminary results of review
in accordance with sections 751(a)(1) and 777(i)(1) of the Act, and 19
CFR 351.221(b)(4).
Dated: May 11, 2026.
Christopher Abbott,
Deputy Assistant Secretary for Policy Assistant Secretary, performing
the non-exclusive functions and duties of the Assistant Secretary for
Enforcement and Compliance.
Appendix I
List of Topics Discussed in the Preliminary Decision Memorandum
I. Summary
II. Background
III. Scope of the Order
IV. Application of Facts Available and Use of Adverse Inferences
V. Recommendation
Appendix II
Companies for Which the Review Has Been Rescinded
1. Aditya Chemicals
2. Adwith Nutrichem Private Limited
3. Avid Organics Private Limited (Avid)
4. Bajaj Healthcare Limited
5. Elementis Specialties India Private Limited
6. Euroasias Organics Private Limited
7. Euroasia Trans Continental
8. Galaxy Surfactants Limited
9. Glisten Biotech
10. Grauer & Weil (India) Limited
11. Gujarat Ambuja Export Limited
12. Gulbrandsen Technologies (India) Private Limited
13. Indiana Chem Port
14. Kronox Lab Sciences Private Limited
15. Mass Dye Chem. Private Limited
16. Meteoric Biopharmaceuticals Private Limited
17. Mulji Mehta Pharma
18. Mumbai Merchant
19. Nature Bio
20. Paras Intermediates Private Limited
21. Priya Chemicals
22. Promois International Limited
23. Shari Pharmachem Private Limited
24. Strava Healthcare Private Limited
25. Tarkesh Trading Company
26. Valaji Pharma Chem
27. Venus International Exports Private Limited
[FR Doc. 2026-09715 Filed 5-13-26; 8:45 am]
BILLING CODE 3510-DS-P
</pre></body>
</html>Indexed from Federal Register on May 14, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.